Overwhelming Efficacy Proven in Phase 3 Trial, Poised to Reshape the Market

Takeda Pharmaceutical Company Limited's (TAK) oral TYK2 inhibitor, zasocitinib (TAK-279), has demonstrated superior efficacy compared to Bristol Myers Squibb's (BMY) existing treatment, Sotyktu (deucravacitinib), in the Phase 3 'LATITUDE Atlas' trial involving 606 patients with moderate-to-severe plaque psoriasis. At week 16, zasocitinib achieved a PASI 100 response rate of over 35%, demonstrating more than 2.5 times higher efficacy compared to Sotyktu. A significant difference in efficacy between the two drugs was observed as early as week 8, and statistical superiority was also achieved in all key secondary endpoints, including PASI 90 and sPGA 0.

Financial Justification for the Nimbus Acquisition

This success validates Takeda's decision to acquire Nimbus Therapeutics in late 2022 for up to $6 billion to gain access to zasocitinib. At the time, Takeda paid $4 billion upfront and agreed to pay up to $2 billion in sales milestones upon reaching annual net sales of $4 billion and $5 billion, respectively. By demonstrating superior efficacy in a head-to-head clinical trial, Takeda has dispelled industry concerns about acquiring a late-stage asset at a high price and firmly established its value. This suggests that zasocitinib will be a key driver of Takeda's long-term growth and a cornerstone of its autoimmune disease portfolio.

A Generational Shift in the Psoriasis Market and the Rise of Oral Therapies

The global psoriasis market is estimated at $23.3 billion to $34.1 billion in 2025 and is expected to continue growing at a high rate of 8% to 11% annually, exceeding $70 billion by the mid-2030s. BMS's Sotyktu, the first oral TYK2 inhibitor to enter the market, received FDA approval in September 2022, but its global sales in 2025 were only $291 million, and its growth has been slow. This clinical trial is likely to further narrow Sotyktu's market position. In particular, BMS's announcement in March 2026 that it would discontinue promotion in the dermatology field, despite obtaining approval for Sotyktu for active psoriatic arthritis, indicates that the market leadership in oral psoriasis treatments is rapidly shifting to Takeda.

Accelerated Commercialization and Expansion into New Territories

Based on these results, Takeda plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and other regulatory agencies within the 2026 fiscal year and aims to launch the product in the first half of 2027. Furthermore, Takeda plans to maximize the value of the drug by expanding its indications to include psoriatic arthritis and inflammatory bowel disease (IBD), in addition to plaque psoriasis. However, competition is expected to intensify as Johnson & Johnson's (J&J) oral IL-23R inhibitor, icotrokinra (ICOTYDE), which received FDA approval in March 2026, and AbbVie's biologic, Skyrizi (risankizumab), continue to maintain a strong presence in the injectable market.